Consideration of antibacterial medicines as part of the revisions to 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for Children (EMLc): Section 6.2 Antibacterials: including Access, Watch and Reserve Lists of antibiotics

Simple item page
dc.coverageCopenhagen
dc.creatorWorld Health Organization. Regional Office for Europe
dc.date2021-10-05T11:52:16Z
dc.date2021-10-05T11:52:16Z
dc.date2018-12-31
dc.date.accessioned2026-08-03T14:53:26Z
dc.description31 p.
dc.descriptionThis summary has been prepared by the Health Technologies and Pharmaceuticals (HTP) programme at the WHO Regional Office for Europe. It is intended to communicate changes to the 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for children (EMLc) to national counterparts involved in the evidence-based selection of medicines for inclusion in national essential medicines lists (NEMLs), lists of medicines for inclusion in reimbursement programs, and medicine formularies for use in primary, secondary and tertiary care. This document does not replace the full report of the WHO Expert Committee, 2017 and this summary should be read in conjunction with the full report.
dc.formatapplication/pdf
dc.identifierhttps://iris.who.int/handle/10665/345890
dc.identifier.urihttps://repo.dare.co.zw/handle/123456789/270334
dc.languageEnglish
dc.languageen
dc.publisherWorld Health Organization. Regional Office for Europe
dc.subjectMedicine
dc.subjectAnti-Bacterial Agents
dc.subjectDrugs, Essential
dc.subjectDrug Information Services
dc.subjectDrug Utilization
dc.subjectChild
dc.titleConsideration of antibacterial medicines as part of the revisions to 2017 WHO Model List of Essential Medicines for adults (EML) and Model List of Essential Medicines for Children (EMLc): Section 6.2 Antibacterials: including Access, Watch and Reserve Lists of antibiotics
dc.typeTechnical Documents

Files

Collections

WHO IRIS